Table 1.
Characteristics and outcome of patients with HCV-related cirrhosis classified according to MCP1, CCR5 and SDF-1 genotypes
|
MCP1 genotype (n = 98) |
CCR5 genotype (n = 120) |
SDF-1 genotype (n = 120) |
|||||||
| MCP-1/MCP-1 homozygotes | Heterozygotes or homozygotes for MCP-1 (-2518) allele | CCR5/CCR5 homozygotes | Heterozygotes or homozygotes for CCR5Δ32 allele | SDF-1/SDF-1 homozygotes | Heterozygotes or homozygotes for SDF-1 3’A allele | ||||
| (n = 56) | (n = 42) | P | (n = 106) | (n = 14) | P | (n = 65) | (n = 55) | P | |
| 57.2% | 42.8% | 88.4% | 11.6% | 54.1% | 45.9% | ||||
| Age (yr)12 | 58.7 ± 12.3 | 58.5 ± 11.8 | 0.9 | 58.7 ± 12.1 | 56.6 ± 13.1 | 0.7 | 57.3 ± 11.5 | 59.8 ± 13.0 | 0.1 |
| Male gender13 | 31 (55.3) | 17 (40.4) | 0.1 | 53 (50.0) | 8 (57.1) | 0.7 | 35 (53.8) | 25 (45.4) | 0.4 |
| ALT (× ULN)12 | 2.6 ± 1.0 | 2.9 ± 1.2 | 0.5 | 2.8 ± 1.2 | 2.2 ± 0.6 | 0.03 | 2.7 ± 1.8 | 2.8 ± 1.1 | 0.7 |
| AST (× ULN)12 | 2.1 ± 0.8 | 2.1 ± 0.7 | 0.9 | 2.2 ± 0.8 | 1.6 ± 0.6 | 0.008 | 2.1 ± 0.8 | 2.2 ± 0.9 | 0.6 |
| Platelet count (103/mm3)12 | 138.3 ± 64.7 | 142.8 ± 65.0 | 0.5 | 138.3 ± 64.7 | 142.8 ± 65.0 | 0.5 | 128.6 ± 60.1 | 152.9 ± 71.3 | 0.07 |
| Child Pugh score12 | 5.1 ± 0.6 | 5.1 ± 0.7 | 0.4 | 5.2 ± 0.7 | 5.0 ± 0.2 | 0.6 | 5.2 ± 0.8 | 5.1 ± 0.5 | 0.2 |
| MCP1 serum levels (pg/mL)12 | 448 ± 150 | 564 ± 168 | 0.9 | - | - | - | - | - | - |
| RANTES serum levels (pg/mL)12 | - | - | - | 28847 ± 18878 | 29576 ± 15905 | 0.6 | - | - | - |
| SDF-1 serum levels (pg/mL)12 | - | - | - | - | - | - | 2347 ± 690 | 2201 ± 333 | 0.7 |
| HCV genotype 13 | 40 (71.4) | 35 (83.3) | 0.2 | 82 (77.3) | 13 (92.8) | 0.2 | 49 (75.3) | 46 (83.6) | 0.3 |
| Anti-viral treatment3 | 32 (57.1) | 26 (61.9) | 0.6 | 62 (58.4) | 10 (71.4) | 0.4 | 44 67.9) | 28 (52.7) | 0.1 |
| Sustained virological3 Response | 14 (25.0) | 11 (26.1) | 0.9 | 25 (23.5) | 3 (21.4) | 0.9 | 16 (24.6) | 12 (21.8) | 0.8 |
| HCC development3 | 17 (30.3) | 19 (45.2) | 0.1 | 43 (40.5) | 4 (28.5) | 0.5 | 26 (40.0) | 21 (38.1) | 0.7 |
| Death3 | 10 (17.8) | 6 (14.2) | 0.7 | 20 (18.8) | 3 (21.4) | 0.7 | 11 (16.9) | 12 (21.8) | 0.4 |
1
Parameters recorded at inclusion.
2
mean ± SD.
3
Number (percentage) of patients. ALT: Alanine aminotransferase; AST: Aspartate transaminase; HCV: Hepatitis C virus; HCC: Hepatocellular carcinoma occurrence.